Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma

Sneha Berry; Janis M Taube

doi:10.1080/2162402X.2015.1029704

Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma

Oncoimmunology. 2015 May 27;4(10):e1029704. doi: 10.1080/2162402X.2015.1029704. eCollection 2015 Oct.

Authors

Sneha Berry¹, Janis M Taube²

Affiliations

¹ Department of Oncology; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ; Baltimore, MD USA.
² Department of Oncology; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ; Baltimore, MD USA ; Department of Dermatology and Department of Pathology; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ; Baltimore, MD USA.

Abstract

Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism-one of "adaptive immune resistance" in which PD-L1 expression is primarily driven by cytokine induction and is independent of BRAF mutational status.

Keywords: BRAF; PD-L1; TIL; adaptive immune resistance; melanoma.